Administrative Core

行政核心

基本信息

批准号：
7669991
负责人：
Myron Max Levine
金额：
$ 61.28万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-03 至 2014-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7669991
关键词：
Acinetobacter Acute Address American Type Culture Collection Americas Andes Virus Animals Anthrax disease Antiviral Agents Arts Attenuated Australian bat lyssaviruses Award Bacillus anthracis Bacteremia Bacteria Binding Biological Biological Assay Biology Biotechnology Bioterrorism Bolivian Hemorrhagic Fever Virus Botulinum Toxins Burkholderia mallei Burkholderia pseudomallei Categories Cells Cherry - dietary Clostridium difficile Clostridium perfringens Colitis Collaborations Communicable Diseases Complex Cryptosporidium Detection Development Diagnostic Diarrhea Disease Disease Outbreaks Doctor of Medicine Doctor of Philosophy Drug resistance Dysentery Elements Enteral Enterotoxins Escherichia coli EHEC Evaluation Event Evolution Face Filovirus Fluorescence Fostering Francisella tularensis Frankfurt-Marburg Syndrome Virus Funding Gastrointestinal Diseases Generic Drugs Genetic Variation Genus Phlebovirus Glanders Goals Hantavirus Health Health Sciences Hemolytic-Uremic Syndrome Hendra Virus Host Defense Mechanism Housing Human Immune Immune response Immune system Individual Infection Institutes Institution Intestines Invaded Junin virus K-Series Research Career Programs Knowledge Laboratories Lead Licensure Life Light Maryland Melioidosis Metals Methodology Methods Microbiology Mission Modality Molecular Mollies Monkeypox virus Mucous Membrane Myron National Institute of Allergy and Infectious Disease Nature Nucleic Acids Orthopoxvirus Paramyxovirus Pathogenesis Pathway interactions Pattern Pennsylvania Phase I Clinical Trials Population Prevention strategy Principal Investigator Process Proteomics Protozoa Public Health Puumala virus RNA RNA Interference Readiness Reproduction spores Research Research Personnel Research Project Grants Resistance Resources Respiratory System Respiratory tract structure Rhabdoviridae Ribosomal RNA Ricin Rift Valley fever virus Salmonella Salmonella paratyphi Salmonella typhi Sampling Scientist Screening procedure Senior Scientist Sepsis Series Services Shiga Toxin Shigella Sin Nombre virus Smallpox Smallpox Viruses Southeastern Asia Staphylococcus aureus Surface System Tacaribe Complex Viruses Techniques Technology Therapeutic Therapeutic Agents Therapeutic Intervention Time Topoisomerase Toxin Translational Research Tularemia Typhoid Fever United States Universities Upper arm Vaccines Viral Virginia Virulence Virulence Factors Virus Whole Blood Work Yersinia pestis anthrax toxin authority base biodefense cellular targeting commercialization comparative design drug discovery enteric pathogen enteroaggregative Escherichia coli enterotoxigenic Escherichia coli expectation gastrointestinal high risk high throughput screening inhibitor/antagonist innovation medical schools member method development microorganism microwave electromagnetic radiation nonhuman primate novel novel diagnostics novel therapeutics oral vaccine pathogen product development professor programs prophylactic rapid detection respiratory response small molecule therapeutic target vaccine candidate vaccine development virus host interaction

项目摘要

The MARCE consortium fosters research that contributes to the defense of the population of the United States of America against biological threats including the deliberate release of bioterror agents and the natural emergence or re-emergence of infectious diseases. As part of its formally defined mission, the MARCE also maintains interactions with public health authorities within the Middle Atlantic Region so that if the need arises, the consortium can mobilize its technical resources to assist the region's public health authorities in the face of a large or unusual outbreak of disease, presumed bioterror incident or other catastrophe. The MARCE consortium that is proposed for the funding cycle of 2009-2014 (MARCE-2) encompasses approximately 65 scientists from 27 research institutions who will engage in a series of collaborative research projects (the vast majority of which represent collaborations that extend across institutional boundaries). Dr. Myron M. Levine, M.D., D.T.P.H., the Grollman Distinguished Professor and Director of the Center for Vaccine Development of the University of Maryland School of Medicine, will continue to serve as the Principal Investigator and Director of the MARCE. Dr. Alison O'Brien, Ph.D., Professor and Chair of the Department of Microbiology of the Uniformed Services University of the Health Sciences, will continue to serve as Co- Principal Investigator. Figure 4-1 in Section A4 provides an overview organizational chart of MARCE-2.

MARCE 联盟促进有助于保卫美国人民的研究美利坚合众国应对生物威胁，包括故意释放生物恐怖分子和自然灾害传染病的出现或重新出现。作为其正式定义的使命的一部分，MARCE 还与中大西洋地区的公共卫生当局保持互动，以便在需要时，该联盟可以调动其技术资源来协助该地区的公共卫生当局应对大规模或不寻常的疾病爆发、推测的生物恐怖事件或其他灾难。马尔斯拟议的 2009-2014 年资助周期 (MARCE-2) 财团包括约 65 来自27个研究机构的科学家将参与一系列合作研究项目（其中绝大多数代表了跨越机构边界的合作）。迈伦·M.博士 Levine，医学博士，D.T.P.H.，格罗尔曼杰出教授兼疫苗中心主任马里兰大学医学院发展，将继续担任校长 MARCE 的研究员和主任。 Alison O'Brien 博士，博士，教授兼系主任统一服务健康科学大学的微生物学将继续担任联合首席研究员。 A4 节中的图 4-1 提供了 MARCE-2 的组织结构图。